When we covered JP Morgan in January, over and over we heard that neurodegenerative diseases, especially Alzheimer’s, were going to be one of the most exciting spaces in pharma this year. And it certainly has been – most recently with the FDA approval of ground-breaking disease-altering therapy leqanemab, which has a competitor, Lilly’s donanemab, coming […]
